Does Aspirin Have a Protective Role Against Chemotherapeutically Induced Ototoxicity?
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00578760|
Recruitment Status : Unknown
Verified December 2007 by University Health Network, Toronto.
Recruitment status was: Not yet recruiting
First Posted : December 21, 2007
Last Update Posted : December 21, 2007
Aspirin (ASA) has been shown, in an animal model, to attenuate the ototoxic properties of cisplatin. The researchers plan to investigate this in patients undergoing cisplatin chemotherapy.
The researchers hypothesise that low-dose aspirin can prevent cisplatin induced ototoxicity in the clinical setting.
|Condition or disease||Intervention/treatment||Phase|
|Hearing Loss Ototoxicity||Drug: aspirin Drug: placebo||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||110 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Does Aspirin Have a Protective Role Against Chemotherapeutically Induced Ototoxicity?|
|Study Start Date :||February 2008|
|Estimated Study Completion Date :||February 2010|
Placebo Comparator: 2
placebo OD during course of chemotherapy
OD for course of cisplatin chemotherapy
325mg ASA OD during course of chemotherapy
325mg ASA OD for the duration of the cisplatin
- hearing loss [ Time Frame: before and after chemotherapy ]
- hearing loss and tinnitus questionnaires [ Time Frame: before and after cisplatin treatment ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00578760
|Contact: Emma Barker, FRCS, PhD||001-416-946-4501 ext email@example.com|
|Princess Margaret Hospital|
|Toronto, Ontario, Canada|
|Sub-Investigator: Emma Barker, FRCS, PhD|